BRIEF-CSL Partners On New Coagulation Treatment

Reuters

Sep 16

Sept 16 (Reuters) - CSL Ltd CSL.AX:

CSL PARTNERS ON NEW COAGULATION TREATMENT
ENTERED INTO AN AGREEMENT WITH PRIVATELY HELD DUTCH BIOTECH COMPANY, VARMX BV
AGREEMENT TO DEVELOP A NEW TREATMENT TO RESTORE BLOOD COAGULATION IN PATIENTS TAKING A FXA INHIBITOR
WILL MAKE AN UPFRONT PAYMENT TO VARMX OF US$117 MILLION FOR AN EXCLUSIVE OPTION TO ACQUIRE COMPANY
VARMX WILL RECEIVE PAYMENTS OF UP TO US$388 MILLION UP TO LAUNCH OF VMX-C001, PLUS FURTHER COMMERCIAL MILESTONES THEREAFTER

Further company coverage: CSL.AX

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2567243121"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2567243121\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2567243121?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-16 09:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2567243121","market":"us","top_or_hot":-1,"title":"BRIEF-CSL Partners On New Coagulation Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-CSL Partners On New Coagulation Treatment</title></head><body><p><span>Sept 16 (Reuters)</span><span> - </span>CSL Ltd <span>CSL.AX</span>:</p><ul><li><p>CSL PARTNERS ON NEW COAGULATION TREATMENT</p></li><li><p>ENTERED INTO AN AGREEMENT WITH PRIVATELY HELD DUTCH BIOTECH COMPANY, VARMX BV</p></li><li><p>AGREEMENT TO DEVELOP A NEW TREATMENT TO <a href=\"https://laohu8.com/S/RST.UK\">RESTORE</a> BLOOD COAGULATION IN PATIENTS TAKING A FXA INHIBITOR</p></li><li><p>WILL MAKE AN UPFRONT PAYMENT TO VARMX OF US$117 MILLION FOR AN EXCLUSIVE OPTION TO ACQUIRE COMPANY</p></li><li><p>VARMX WILL RECEIVE PAYMENTS OF UP TO US$388 MILLION UP TO LAUNCH OF VMX-C001, PLUS FURTHER COMMERCIAL MILESTONES THEREAFTER</p></li></ul><p>Further company coverage: <span>CSL.AX</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-CSL Partners On New Coagulation Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-CSL Partners On New Coagulation Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-16 09:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-CSL Partners On New Coagulation Treatment</title></head><body><p><span>Sept 16 (Reuters)</span><span> - </span>CSL Ltd <span>CSL.AX</span>:</p><ul><li><p>CSL PARTNERS ON NEW COAGULATION TREATMENT</p></li><li><p>ENTERED INTO AN AGREEMENT WITH PRIVATELY HELD DUTCH BIOTECH COMPANY, VARMX BV</p></li><li><p>AGREEMENT TO DEVELOP A NEW TREATMENT TO <a href=\"https://laohu8.com/S/RST.UK\">RESTORE</a> BLOOD COAGULATION IN PATIENTS TAKING A FXA INHIBITOR</p></li><li><p>WILL MAKE AN UPFRONT PAYMENT TO VARMX OF US$117 MILLION FOR AN EXCLUSIVE OPTION TO ACQUIRE COMPANY</p></li><li><p>VARMX WILL RECEIVE PAYMENTS OF UP TO US$388 MILLION UP TO LAUNCH OF VMX-C001, PLUS FURTHER COMMERCIAL MILESTONES THEREAFTER</p></li></ul><p>Further company coverage: <span>CSL.AX</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250916:nFWN3V2176:1","article_id":"2567243121","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2567243121","pubTimestamp":1757985568,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-CSL Partners On New Coagulation TreatmentSept 16  - CSL Ltd CSL.AX:CSL PARTNERS ON NEW COAGULATION TREATMENTENTERED INTO AN AGREEMENT WITH PRIVATELY HELD DUTCH BIOTECH COMPANY, VARMX BVAGREEMENT TO DEVELOP A NEW TREATMENT TO RESTORE BLOOD COAGULATION IN PATIENTS TAKING A FXA INHIBITORWILL MAKE AN UPFRONT PAYMENT TO VARMX OF US$117 MILLION FOR AN EXCLUSIVE OPTION TO ACQUIRE COMPANYVARMX WILL RECEIVE PAYMENTS OF UP TO US$388 MILLION UP TO LAUNCH OF VMX-C001, PLUS FURTHER COMMERCIAL MILESTONES THEREAFTERFurther company coverage: CSL.AX ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","BK7508":"医药生物股","BK7511":"ESG概念","BK7501":"新冠治疗股","CSL.AU":"CSL LIMITED"},"translate_title":"简介-CSL合作伙伴合作开发新型凝血治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL.AU":0.9},"content_text":"BRIEF-CSL Partners On New Coagulation TreatmentSept 16 (Reuters) - CSL Ltd CSL.AX:CSL PARTNERS ON NEW COAGULATION TREATMENTENTERED INTO AN AGREEMENT WITH PRIVATELY HELD DUTCH BIOTECH COMPANY, VARMX BVAGREEMENT TO DEVELOP A NEW TREATMENT TO RESTORE BLOOD COAGULATION IN PATIENTS TAKING A FXA INHIBITORWILL MAKE AN UPFRONT PAYMENT TO VARMX OF US$117 MILLION FOR AN EXCLUSIVE OPTION TO ACQUIRE COMPANYVARMX WILL RECEIVE PAYMENTS OF UP TO US$388 MILLION UP TO LAUNCH OF VMX-C001, PLUS FURTHER COMMERCIAL MILESTONES THEREAFTERFurther company coverage: CSL.AX ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}